<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01276912</url>
  </required_header>
  <id_info>
    <org_study_id>STOP-GO-2010</org_study_id>
    <nct_id>NCT01276912</nct_id>
  </id_info>
  <brief_title>Study TO Prevent Diabetes With Short-term Insulin Glargine Only</brief_title>
  <acronym>STOP-GO</acronym>
  <official_title>A Multicenter, Randomized, Controlled Trial to Prevent Diabetes With Short-term Insulin Glargine Treatment or Lifestyle Intervention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Tongren Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Tongren Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  Pre-diabetes is a significant risk factor for the development of type 2 diabetes, as&#xD;
           well as macrovascular and microvascular complication.&#xD;
&#xD;
        -  Previous studies show that 50% or more loss in islet B-cell function even in&#xD;
           Pre-diabetes phase. The early insulin therapy in pre-diabetes may be a strategy in&#xD;
           preventing metabolic disorders and cardiovascular disease.&#xD;
&#xD;
        -  The objective of this study is to find if an initial insulin glargine intervention in&#xD;
           pre-diabetes (IGT and /or IFG) could be a strategy in preventing type 2 Diabetes.&#xD;
&#xD;
        -  Pre-diabetes subjects will receive a insulin glargine therapy with a dosage adjusted to&#xD;
           get FBG ≤ 5.3mmol / L as the goal. Insulin glargine treatment will be maintained for&#xD;
           three months thereafter to find if it can prevent diabetes.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2011</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">October 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HbA1c &gt;= 6.5%</measure>
    <time_frame>Two years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>FPG &gt;= 7.0 for two times in a month.</measure>
    <time_frame>Two years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c &gt;= 7.0%</measure>
    <time_frame>Two years</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">2420</enrollment>
  <condition>Pre-diabetes</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin glargine</intervention_name>
    <description>Insulin glargine therapy with a dosage adjusted to get FBG ≤ 5.3mmol / L as the goal, accompanied with a lifestyle counseling.</description>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Lifestyle counseling</intervention_name>
    <description>To give lifestyle guidance, specifically including low fat, low saturated fatty acids, rich in dietary fiber, salt restriction, limit alcohol diet plan to reduce the 5% to 10% of body weight, and to ensure a regular moderate physical activity at least 150 minutes per week.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. All participants are voluntary and write informed consent 2 weeks before enrollment.&#xD;
&#xD;
          2. Fasting Blood Glucose between &gt;= 5.6mmol/L and &lt;7.0mmol/L, and HbA1c between &gt;= 5.7%&#xD;
             and &lt;6.5%.&#xD;
&#xD;
          3. Both male and female aged between &gt;= 25 and ≤ 65 years.&#xD;
&#xD;
          4. Participants have the ability to use self-monitoring devices to measure their blood&#xD;
             glucose level and practice self-insulin injection.&#xD;
&#xD;
          5. Have the ability and willingness to complete the study logs and questionnaires.&#xD;
&#xD;
          6. Pregnancy test of all child-bearing age women should be negative, and they agree to&#xD;
             adopt contraceptive measures in the study process.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. With previous diagnosis of diabetes or application of hypoglycemic drugs.&#xD;
&#xD;
          2. Preliminary screen for fasting plasma glucose lever ≥7.0mmol/L or &lt;5.6mmol/L.&#xD;
&#xD;
          3. Preliminary screen for HbA1c result HbA1c&lt;5.7% or ≥ 6.5%.&#xD;
&#xD;
          4. Receiving cancer treatment in the past 5 years.&#xD;
&#xD;
          5. Preliminary diagnostic anti-HIV test result positive, with no serological testing.&#xD;
&#xD;
          6. People with active tuberculosis.&#xD;
&#xD;
          7. Persons hospitalized for heart disease and received the treatment measures (such as&#xD;
             coronary artery bypass graft CABG, percutaneous transluminal coronary angioplasty&#xD;
             PTCA), while not include diagnostic measures (such as percutaneous coronary&#xD;
             angiography) in the past 6 months.&#xD;
&#xD;
          8. Cardiac function evaluated by New York Heart Association criteria (NYHA) ≥ 3 cardiac&#xD;
             function level&#xD;
&#xD;
          9. Uncontrolled high blood pressure - systolic blood pressure &gt; 180mmHg or diastolic&#xD;
             blood pressure &gt; 105mmHg after treatment.&#xD;
&#xD;
         10. Stroke or transient ischemic attack episode in the past 6 months.&#xD;
&#xD;
         11. With chronic hepatitis or active liver disease, or serum AST or ALT 2.5 times the&#xD;
             upper limit of normal.&#xD;
&#xD;
         12. Male serum creatinine ≥ 124μmol/L (1.4mg/dL); Female serum creatinine ≥ 115μmol/L&#xD;
             (1.3mg/dL).&#xD;
&#xD;
         13. Systemic glucocorticoids applications, but other than local, eye, and inhalation&#xD;
             applications.&#xD;
&#xD;
         14. Anemia: male hematocrit &lt;36.0%; female &lt;33.0%.&#xD;
&#xD;
         15. Other chronic diseases which may lead to the expected life less than 6 years or&#xD;
             conditions that may affect life expectancy.&#xD;
&#xD;
         16. Mental disorder history.&#xD;
&#xD;
         17. Alcohol consumption (average 50g or more high spirits drink or 100g or more low&#xD;
             spirits drink) or drug abuse.&#xD;
&#xD;
         18. Unable or unwilling to sign informed consent.&#xD;
&#xD;
         19. Cannot communicate or contact with the clinical staff.&#xD;
&#xD;
         20. Unwilling to receive insulin injection therapy or conduct self-monitoring of blood&#xD;
             glucose.&#xD;
&#xD;
         21. Unsatisfied control of thyroid disease - subjects who are suffering thyroid disease or&#xD;
             receiving anti-thyroid drugs or thyroid hormone treatment, show the sensitive TSH&#xD;
             abnormalities (except for patients with low TSH who have the history of thyroid tumor&#xD;
             or thyroid cancer receiving the inhibitor treatment).&#xD;
&#xD;
         22. Any other factors that may affect compliance or adverse events reported during the&#xD;
             research program.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jin-Kui Yang, M.D., Ph.D.</last_name>
    <phone>+86-10-58268445</phone>
    <email>jinkui.yang@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Tongren Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jin-Kui Yang, M.D., Ph.D.</last_name>
      <phone>+86-10-58268445</phone>
      <email>jinkui.yang@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2011</verification_date>
  <study_first_submitted>January 13, 2011</study_first_submitted>
  <study_first_submitted_qc>January 13, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2011</study_first_posted>
  <last_update_submitted>January 13, 2011</last_update_submitted>
  <last_update_submitted_qc>January 13, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 14, 2011</last_update_posted>
  <responsible_party>
    <name_title>Jin-Kui Yang/Professor</name_title>
    <organization>Department of Endocrinology, Beijing Tongren Hospital, Capital Medical University</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Prediabetic State</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Glargine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

